Literature DB >> 1688591

Inhibition of murine relapsing experimental autoimmune encephalomyelitis by immune tolerance to proteolipid protein and its encephalitogenic peptides.

M K Kennedy1, L J Tan, M C Dal Canto, V K Tuohy, Z J Lu, J L Trotter, S D Miller.   

Abstract

Tolerization of SJL/J mice with splenocytes coupled with proteolipid protein (PLP), the major protein component of central nervous system myelin, resulted in dramatic inhibition of relapsing experimental autoimmune encephalomyelitis (R-EAE) induced by mouse spinal cord homogenate (MSCH). Mice tolerized with splenocytes coupled with MSCH (a complex mixture of neuroantigens) or with purified PLP, but not purified myelin basic protein, were resistant to the development of clinical and histologic R-EAE. In addition, mice rendered tolerant to an encephalitogenic peptide of PLP were significantly protected, whereas mice tolerized to a nonencephalitogenic peptide of PLP were highly susceptible, to the induction of MSCH-induced R-EAE. Thus, immune responses directed against encephalitogenic regions of PLP appear to play a major role in the development of R-EAE induced by MSCH in SJL/J mice. These results also indicate that determinant-specific immune tolerance is a feasible approach to the regulation of a disease that involves autoimmune responses to a variety of Ag.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1688591

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  40 in total

1.  The inverse of immunity.

Authors:  Elie Dolgin
Journal:  Nat Med       Date:  2010-07       Impact factor: 53.440

2.  Pathogenesis of NOD diabetes is initiated by reactivity to the insulin B chain 9-23 epitope and involves functional epitope spreading.

Authors:  Suchitra Prasad; Adam P Kohm; Jeffrey S McMahon; Xunrong Luo; Stephen D Miller
Journal:  J Autoimmun       Date:  2012-05-28       Impact factor: 7.094

3.  Antigen-specific therapy of experimental allergic encephalomyelitis by soluble class II major histocompatibility complex-peptide complexes.

Authors:  S D Sharma; B Nag; X M Su; D Green; E Spack; B R Clark; S Sriram
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-15       Impact factor: 11.205

4.  Multi-peptide coupled-cell tolerance ameliorates ongoing relapsing EAE associated with multiple pathogenic autoreactivities.

Authors:  Cassandra E Smith; Stephen D Miller
Journal:  J Autoimmun       Date:  2006-12       Impact factor: 7.094

Review 5.  Molecular mechanisms of T-cell receptor and costimulatory molecule ligation/blockade in autoimmune disease therapy.

Authors:  Joseph R Podojil; Stephen D Miller
Journal:  Immunol Rev       Date:  2009-05       Impact factor: 12.988

Review 6.  Tolerance strategies employing antigen-coupled apoptotic cells and carboxylated PLG nanoparticles for the treatment of type 1 diabetes.

Authors:  Suchitra Prasad; Dan Xu; Stephen D Miller
Journal:  Rev Diabet Stud       Date:  2012-12-28

7.  Intrinsic and induced regulation of the age-associated onset of spontaneous experimental autoimmune encephalomyelitis.

Authors:  Hong Zhang; Joseph R Podojil; Xunrong Luo; Stephen D Miller
Journal:  J Immunol       Date:  2008-10-01       Impact factor: 5.422

8.  Fas-mediated apoptosis in clinical remissions of relapsing experimental autoimmune encephalomyelitis.

Authors:  G C Suvannavejh; M C Dal Canto; L A Matis; S D Miller
Journal:  J Clin Invest       Date:  2000-01       Impact factor: 14.808

9.  Designing inorganic nanomaterials for vaccines and immunotherapies.

Authors:  Krystina L Hess; Igor L Medintz; Christopher M Jewell
Journal:  Nano Today       Date:  2019-05-29       Impact factor: 20.722

Review 10.  Antigen-specific tolerance in immunotherapy of Th2-associated allergic diseases.

Authors:  Charles B Smarr; Paul J Bryce; Stephen D Miller
Journal:  Crit Rev Immunol       Date:  2013       Impact factor: 2.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.